

DISTRICT OFFICE
1915 EYE ST NW
WASHINGTON, DC 20006

LONDON OFFICE
ONE GREAT CUMBERLAND PLACE
MARBLE ARCH, LONDON, W1H7AL

LAW OFFICES OF
DAVID E. PRICE
#3 BETHESDA METRO CENTER
SUITE 700
BETHESDA, MD 20814

TEL (202) 536-5191

MONACO OFFICE
SUITE #1, 17 BLVD DE SUISSE
MONACO 98000

ISRAEL OFFICE
DIAMOND TOWER, 28TH FLOOR
3A JABOTINSKI RD., RAMAT-GAN 52520

TopTier.eu

January 7th, 2025

Pink OTC Markets, Inc
304 Hudson Street
2nd Floor
New York, NY 10013

Re: **Easylink Solutions Corp.**
Sufficiency of Adequate Current Information

Dear Pink OTC Markets, Inc.

I have been retained by Easylink Solutions Corp., (ESYL) a Nevada corporation (the "Issuer"), for the purpose of rendering this letter to you with respect to the information publicly disclosed by the Issuer to you and published in the Pink OTC Disclosure and News Service. Pink OTC Markets Inc. is entitled to rely on this letter in determining whether the Issuer has made adequate current information publicly available regarding the Issuer and the common stock of the Issuer (the "Securities") within the meaning of Rule 144(c)(2) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). I hereby consent to having this letter posted by the Issuer, and to have it published, accompanying their disclosure in the Pink OTC Markets News Service. I hereby represent that I am a U.S. resident and that I am licensed to practice law in the United States in the state of Maryland as well as the Courts of the District of Columbia. I have not received, nor have any agreement nor expectation to receive shares of the issuer's stock as payment for my services. I have not been suspended or barred from practicing in any state or jurisdiction, nor charged in a any civil or criminal case. I am permitted to practice before the Securities and Exchange Commission (the "Commission") and I have not been prohibited from practice before the Commission. In addition, I hereby represent that neither I, nor my firm, is currently or has ever been under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

In preparing this letter, I have examined such corporate records and other documents and such questions of law as I considered necessary or appropriate for the purposes of rendering this letter; including the Articles of Incorporation and Bylaws as well as the Amended Annual Report as of December 31st, 2023, posted on OTC Markets on December 30th, 2024. As to matters of fact in this letter, I have relied upon information from public officials, officers of the Issuer and other sources, which sources I believed to be reliable. In such examination, I have assumed the genuineness of all signatures set forth on each document, the authenticity of all original documents and the conformity to original documents of all copies of such documents as may have been supplied to us during the course of my examination.

In issuing this letter, I represent as follows:

1. That the Issuer Disclosure posted on the OTC Disclosure & News Service and publicly available with regard to the Issuer (i) constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934 (the "Exchange Act"), (iii) complies as to form with the Pink OTC Markets Guidelines for Providing Adequate Current Information, which are located on the Internet at www.OTCMarkets.com. Upon investigation, it is my firm legal opinion that the issuer is not, nor has ever been a "shell company" as that term is defined by the Commission as well as the definitions per Rule §405, and §12b-2 of the Exchange Act, whereby the issuer has always had funded and ongoing business operations with implemented business plan, note payables, etc. Additionally, the Company has specifically filed as a "Non-Shell Company" in its filings with OTC, and these reports are publicly available.
2. That the financial statements of the Issuer contained in the Issuer Disclosure were not audited and are prepared by outside accounting. The person responsible for the preparation of the financial statements is Shlomo Zakai, a licensed CPA and outside accountant to the Issuer.
3. That the Issuer's Transfer Agent, which is registered with the SEC, is Pacific Stock Transfer, which updates the Issuer's securities monthly on OTC and has provided the issuer's most recent issuances as reflected in the official Shareholder's List, as such it is accurate and up-to-date.
4. That I have (i) personally met with the issuer's Director Ran Dror, (ii) reviewed the Issuer Disclosure, as amended, published by the Issuer on the Pink Sheets News Service and (iii) discussed the Issuer Disclosure with management.
5. That to the best of my knowledge, after inquiry of management and the Board of Directors of the Issuer, that neither the Issuer, nor any of its officers and/or directors, or any 5% shareholder is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

The opinions set forth herein are expressed as of the date hereof and remain valid so long as the documents, instruments, records and certificates I have examined and relied upon as noted above, are unchanged and the assumptions I have made, as noted above, are valid. While this letter is intended exclusively for use by Pink OTC Markets, Inc., the same is hereby granted full and complete rights and permission without any future request to publish this letter as part of "OTCMarkets.com" for viewing by the public and regulatory agencies.

Sincerely yours,

A handwritten signature in blue ink, appearing to read "David E. Price", with a stylized flourish at the end.

David E. Price, Esq.

DEP/mc

cc: Mr. Ran Dror, Dir.

Mr. Asaf Azulay, Dir.